Civitas Therapeutics

28 articles about Civitas Therapeutics

• 

  Acorda Therapeutics CTO Leaves To Helm Unnamed Biotech Company

  8/14/2018

  Acorda Therapeutics Chief Technology Officer Rick Batycky is leaving the company to take over the helm of an unnamed biotechnology company.

• Cowen: Acorda Therapeutics Not Worried About Civitas Therapeutics' New Parkinson's Drug

  11/20/2014

• Acorda Therapeutics Completes Acquisition Of Civitas Therapeutics

  10/23/2014

• Acorda Therapeutics Snaps Up Civitas Therapeutics In $525M Cash Deal

  9/24/2014

• A Day After Nabbing $55 Million, Parkinson's Biotech Civitas Therapeutics Files For $86 Million IPO

  8/27/2014

• Massachusetts' Civitas Therapeutics Locks In $55 Million

  8/26/2014

• Civitas Therapeutics Announces Positive Phase 2b Results For CVT-301, Inhaled Levodopa For The Treatment Of Parkinson’s Disease

  4/28/2014

• Civitas Therapeutics To Present At The 21st Annual Future Leaders In The Biotech Industry Conference

  3/24/2014

• Civitas Therapeutics To Present At Cowen and Company 34th Annual Health Care Conference

  2/25/2014

• Civitas Therapeutics To Present At 2014 Leerink Swann and Company Global Healthcare Conference

  2/6/2014

• Civitas Therapeutics Appoints Mark Iwicki President And Chief Executive Officer

  1/29/2014

• Civitas Therapeutics Appoints Timothy S. Nelson As Chairman Of The Board Of Directors

  1/8/2014

• Civitas Therapeutics To Present At Piper Jaffray And Oppenheimer Investor Conferences In December

  11/26/2013

• Civitas Therapeutics Extends CVT-301 Patent Protection Into 2032

  11/8/2013

• Civitas Therapeutics Raises $38 Million

  9/11/2013

• Civitas Therapeutics Initiates Phase 2b Clinical Study of CVT-301, Inhaled L-dopa for Parkinson’s Disease

  9/5/2013

• Civitas Therapeutics to Present at Wedbush Securities and Canaccord Genuity Investor Conferences in August

  8/7/2013

• Civitas Therapeutics to Present at JMP Securities Healthcare Conference

  7/2/2013

• Civitas Therapeutics Receives Second Grant for Their Lead Product CVT-301 From The Michael J. Fox Foundation for Parkinson’s Research

  6/18/2013

• Civitas Therapeutics to Present at Jefferies and Co. 2013 Global Healthcare Conference

  5/29/2013